2023 World Conference on Lung Cancer (Posters)-P1.23. Liquid Biopsy Predicts Differential Benefit from First Line Pembrolizumab in Advanced Non-small Cell Lung Cancer

P1.23. Liquid Biopsy Predicts Differential Benefit from First Line Pembrolizumab in Advanced Non-small Cell Lung Cancer - PDF(Abstract)

Back to course

Pdf Summary

This study presented at the WCLC 2023 conference investigated the use of liquid biopsy as a predictive marker for the clinical benefit of first-line pembrolizumab treatment in advanced non-small cell lung cancer (aNSCLC) patients. The study enrolled aNSCLC patients who were treated with pembrolizumab and performed liquid biopsies at baseline and after three weeks of treatment. The liquid biopsies were evaluated for cell free DNA (cfDNA) quantification and analyzed for tumor-associated genetic alterations using a NGS panel.<br /><br />The results showed that patients who had higher levels of tumor-associated genetic alterations at baseline had a worse response to pembrolizumab treatment. Additionally, patients who experienced early death or had worse progression-free survival and overall survival had higher levels of tumor-associated genetic alterations at the second liquid biopsy. These findings suggest that liquid biopsy can predict the outcome of pembrolizumab treatment, even in patients with high levels of PDL-1 expression.<br /><br />The study concludes that liquid biopsy can be used as a tool to customize first-line treatment strategies for aNSCLC patients. By identifying patients who are likely to derive detrimental effects from pembrolizumab treatment, liquid biopsy can help optimize treatment decisions and potentially improve patient outcomes.<br /><br />Overall, this study highlights the potential of liquid biopsy as a predictive marker in immunotherapy for aNSCLC patients, providing valuable insights for personalized treatment approaches.

Asset Subtitle

Laura Bonanno

Meta Tag

Speaker Laura Bonanno

Topic Pathology & Biomarkers: Liquid Based Biomarkers

Keywords

liquid biopsy

predictive marker

first-line pembrolizumab treatment

advanced non-small cell lung cancer

aNSCLC

cell free DNA

tumor-associated genetic alterations

NGS panel

progression-free survival

overall survival